Purified polypeptide of human papillomavirus type 49 (HPV49) type 50 (HVP50), and type 55 (HPV55)

• US 5,824,466 A
• Filed: 04/20/1996
• Issued: 10/20/1998
• Est. Priority Date: 05/13/1988
• Status: Expired due to Term

• Current Assignee: Roche Molecular Systems (Roche Holding AG)
• Original Assignee: Institut National De La Sante Et De La Recherche Medicale (Inserm) (Allianz Global Investors GmbH), Institut Pasteur
• Inventors: Kremsdorf, Dina, Orth, Gerard, Pehau-Arnaudet, Gerard, Favre, Michel
• Primary Examiner(s): Knode, Marian C.
• Assistant Examiner(s): SALIMI, ALI REZA
• Application Number:
  US08/626,347
• Time in Patent Office: 913 Days
• Field of Search: 435/69.3, 435/5, 435/2.1, 435/69.1, 435/235.1, 435/252.3, 530/350, 530/387.1, 424/130.1, 424/199.1, 424/204.1
• US Class Current: 435/5
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C07K 16/084 Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
• CPC Class Codes: C12N 2710/20022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12Q 1/708 for papilloma

Abstract

The invention relates to papillomavirus probes derived from new DNA-HPVs deposited with the CNCM on the 6 May 1988 under the following filing numbers:

PGEM 4 HPV49: I-754

PSP 65 HPV50: I-755

PSP 64 HPV54: I-756

PGEM 4 HPV55A: I-757

PGEM 4 HPV55B: I-758

These probes can be used for in vitro detection of:

in the case of HPV49: warts of the skin (in particular, common and plantar warts) and the differential diagnosis of epidermodysplasia verruciformis,

in the case of HPV50: epidermodysplasia verruciformis, intra-epithelial neoplasias and cutaneous cancers,

in the case of HPV55: genital neoplasias and cancers of the uterine cervix,

in the case of HPV55: genital neoplasias and cancers of the uterine cervix, condylomas and papillomas.

Claims

1. A purified polypeptide encoded by a gene of HPV49 selected from the group consisting of E1, E2, E6, E7, L1, and L2.

3. The purified polypeptide of claim 1 or 2, wherein said gene is L2.

2. A purified polypeptide encoded by a gene of HPV49 having Accession Number C.N.C.M. I-754 and said gene is selected from the group consisting of E1, E2, E6, E7, L1, and L2.

4. A purified polypeptide encoded by an E1 gene of HPV49.

9. The purified polypeptide of claim 4 wherein the HPV49 has Accession Number C.N.C.M. I-754.

5. A purified polypeptide encoded by an E2 gene of HPV49.

10. The purified polypeptide of claim 5 wherein the HPV49 has Accession Number C.N.C.M. I-754.

6. A purified polypeptide encoded by an E6-E7 gene of HPV49.

11. The purified polypeptide of claim 6 wherein the HPV49 has Accession Number C.N.C.M. I-754.

7. A purified polypeptide encoded by an L1 gene of HPV49.

12. The purified polypeptide of claim 7 wherein the HPV49 has Accession Number C.N.C.M. I-754.

8. A purified polypeptide encoded by an L2 gene of HPV49.

13. The purified polypeptide of claim 8 wherein the HPV49 has Accession Number C.N.C.M. I-754.

14. A method of producing a peptide encoded by a gene of HPV 49 selected from the group consisting of E1, E2, E6, E7, L1, and L2, comprising the steps of

transforming a host cell with a vector comprising a DNA fragment encoding gene of HPV49 selected from the group consisting of E1, E2, E6, E7, E4, E5, L1, and L2;

culturing said host cell; and

recovering the resulting peptide product.

15. The method of claim 14, wherein said gene is E2.

16. The method of claim 14, wherein said gene is L1.

17. The method of claim 14, wherein said gene is L2.

18. A purified polypeptide encoded by a gene of HPV50 selected from the group consisting of E1, E2, E6, E7, L1, and L2.

20. The purified polypeptide of claim 18 or 19, wherein said gene is L2.

19. A purified polypeptide encoded by a gene of HPV50 having Accession Number C.N.C.M. I-755, and said gene is selected from the group consisting of E1, E2, E6, E7, L1, and L2.

21. A purified polypeptide encoded by an E1 gene of HPV50.

26. The purified polypeptide of claim 21 wherein the HPV50 has Accession Number C.N.C.M. I-755.

22. A purified polypeptide encoded by an E2 gene of HPV50.

27. The purified polypeptide of claim 22 wherein the HPV50 has Accession Number C.N.C.M. I-755.

23. A purified polypeptide encoded by an E6-E7 gene of HPV50.

28. The purified polypeptide of claim 23 wherein the HPV50 has Accession Number C.N.C.M. I-755.

24. A purified polypeptide encoded by an L1 gene of HPV50.

29. The purified polypeptide of claim 24 wherein the HPV50 has Accession Number C.N.C.M. I-755.

25. A purified polypeptide encoded by an L2 gene of HPV50.

30. The purified polypeptide of claim 25 wherein the HPV50 has Accession Number C.N.C.M. I-755.

31. A method of producing a peptide encoded by a gene of HPV 50 selected from the group consisting of E1, E2, E6, E7, L1, and L2, comprising the steps of

transforming a host cell with a vector comprising a DNA fragment encoding gene of HPV50 selected from the group consisting of E1, E2, E6, E7, L1, and L2;

culturing said host cell; and

recovering the resulting peptide product.

32. The method of claim 31, wherein said gene is E2.

33. The method of claim 31, wherein said gene is L1.

34. The method of claim 31, wherein said gene is L2.

35. A purified polypeptide encoded by a gene of HPV55 selected from the group consisting of E1, E2, E6, E7, L1, and L2.

37. The purified polypeptide of claim 35 or 36, wherein said gene is L2.

36. A purified polypeptide encoded by a gene of HPV55 having Accession Number C.N.C.M. I-757 or I-758, wherein said gene is selected from the group consisting of E1, E2, E6, E7, L1, and L2.

38. A purified polypeptide encoded by an E1 gene of HPV55.

43. The purified polypeptide of claim 38, wherein the HPV55 has Accession Number C.N.C.M. I-757 or I-758.

39. A purified polypeptide encoded by an E2 gene of HPV55.

44. The purified polypeptide of claim 39, wherein the HPV55 has Accession Number C.N.C.M. I-757 or I-758.

46. The purified polypeptide of claim 44, wherein the HPV55 has Accession Number C.N.C.M. I-757 or I-758.

40. A purified polypeptide encoded by an E6-E7 gene of HPV55.

45. The purified polypeptide of claim 40, wherein the HPV55 has Accession Number C.N.C.M. I-757 or I-758.

41. A purified polypeptide encoded by an L1 gene of HPV55.

42. A purified polypeptide encoded by an L2 gene of HPV55.

47. The purified polypeptide of claim 42, wherein the HPV55 has Accession Number C.N.C.M. I-757 or I-758.

48. A purified DNA having greater than 50% homology under stringent hybridization conditions with a purified DNA having the nucleotide residue sequence of HPV55 having Accession Number C.N.C.M. I-757 or I-758.

49. A fragment of DNA, wherein said DNA has the nucleotide residue sequence of HPV55 having Accession Number C.N.C.M. I-757 or I-758, and wherein said fragment is selected from the group consisting of genes E1, E2, E6-E7, L1, and L2 of HPV55.

50. A fragment of DNA, wherein said DNA has the nucleotide residue sequence of HPV55 having Accession Number C.N.C.M. I-757 or I-758, and said fragment is the non-coding intergenic region.

51. A method of detecting HPV55 in a biological sample, said method comprising

(a) obtaining the nucleic acid of said biological sample;

(b) contacting said nucleic acid with the isolated and essentially pure HPV55 DNA having the nucleotide residue sequence of HPV55 having Accession Number C.N.C.M. I-757 or I-758, wherein said DNA is labeled with a label selected from the group consisting of a radioactive marker and a non-radioactive marker;

(c) detecting said labeled DNA; and

(d) correlating the presence of said labeled DNA with the presence of HPV55 in said sample.

52. A method of detecting HPV55 in a biological sample, said method comprising

(a) obtaining the nucleic acid of said biological sample;

(b) contacting said nucleic acid with a fragment of DNA, wherein said DNA has the nucleotide residue sequence of HPV55 having the nucleotide residue sequence of HPV55 having Accession Number C.N.C.M. I-757 or I-758, and said fragment is selected from the group consisting of genes E1, E2, E6-E7, L1, and L2 of HPV55, wherein said fragment is labeled with a label selected from the group consisting of a radioactive marker and a non-radioactive marker;

(c) detecting said labeled fragment; and

(d) correlating the presence of said labeled fragment with the presence of HPV55 in said sample.